In partnership with

Start investing right from your phone

Jumping into the stock market might seem intimidating with all its ups and downs, but it’s actually easier than you think. Today’s online brokerages make it simple to buy and trade stocks, ETFs, and options right from your phone or laptop. Many even connect you with experts who can guide you along the way, so you don’t have to figure it all out alone. Get started by opening an account from Money’s list of the Best Online Stock Brokers and start investing with confidence today.

Start investing

Alnylam Pharmaceuticals, Inc DCF Stock Analysis.

Here’s my assumptions:

Risk Free Rate (10 Years Interest Rate Swap): 4.131%

Risk Premium (Taken from the Aswath Damodaran equity premium spreadsheet): 4.33%

Interest Rate Spread on The Risk free rate ( For the cost of debt calculation): 4%

Historical Data

Revenue growth in the last 10 years (CAGR): 49.21%

Earnings growth in the last 10 years (CAGR): -0.42%

Unlevered Free Cash Flow growth in the last 10 years (CAGR): / (from -$140.6M to $199.5M)

Future Assumptions

End of Year FCF growth: 20%

Growth until end of 2026: 40%

Growth until end of 2034: 20%

Perpetual growth: 3.1%

Net Debt: 0.049B

Outstanding Stock Options + Performance Stock Options Present Value Assumption: $1.664B

Stock Valuation based on these assumptions: $257

Last update 11/08/2025

All the content in this newsletter should be taken as informational content only. THIS IS NOT FINANCIAL ADVICE! Do your own Due Diligence before investing or contact a professional financial advisor.

I don’t have a position in Alnylam Pharmaceuticals, Inc (ALNY) and I don’t plan to add a position in the coming days.